У нас вы можете посмотреть бесплатно CheckMate 648: Novel treatment for patients with advanced esophageal squamous cell carcinoma или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Hisato Kawakami, MD, PhD, Kindai University, Osaka, Japan, talks on the Phase III CheckMate 648 (NCT03143153) trial, in which the efficacy of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin was compared to fluorouracil plus cisplatin only in patients with unresectable advanced, recurrent or metastatic previously-untreated esophageal squamous cell carcinoma. Dr Kawakami comments on the several factors which were associated with a delayed therapeutic onset of treatment with nivolumab plus ipilimumab, including age and alcohol use, and the implications of this. Moreover, the Glasgow Prognostic Score (GPS) and its association with the efficacy of nivolumab plus ipilimumab is discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.